Learn More
Forensic facial approximation is used as a tool for recreating the antemortem appearance of unknown dead and thus facilitates their identification. Several approaches to facial approximation are based on data on facial soft tissue thicknesses (FSTTs). The availability of sex-, age- and population-specific data contributes to the accuracy of the resulting(More)
Androgen deprivation therapy (ADT) administered as a prostate cancer treatment is known to exert multiple side effects including bone deterioration leading to bone fracture. The current analysis is to evaluate the burden of fracture risk in the New Zealand prostate cancer (PCa) population treated with ADT, and to understand the subsequent risk of mortality(More)
OBJECTIVE To examine temporal trends and current survival differences between Māori and non-Māori men with prostate cancer in New Zealand (NZ). PATIENTS AND METHODS A cohort of 37,529 men aged ≥ 40 years diagnosed with prostate cancer between 1996 and 2010 was identified from the New Zealand Cancer Registry and followed until 25 May 2011. Cause of death(More)
PURPOSE To assess the patterns of use of androgen deprivation therapy (ADT) and chemotherapeutic agents in New Zealand men with prostate cancer. METHODS Men diagnosed with prostate cancer between 2006 and 2011 were identified from the New Zealand Cancer Registry. Through data linkage with the Pharmaceutical Collection and the National Minimum Dataset(More)
INTRODUCTION Prostate cancer is a common health problem in men worldwide. This systematic review has been undertaken to determine if there are differences in incidence of and mortality from prostate cancer between rural and urban men. The understanding of geographical patterns of prostate cancer incidence and mortality is necessary in order to identify and(More)
OBJECTIVES To examine diagnostic and treatment pathways for Māori (the indigenous people of New Zealand [NZ]) and NZ European men with prostate cancer in order to identify causes of higher mortality rates for Māori men. METHODS All Māori men (150) diagnosed with prostate cancer in the Midland Cancer Network region between 2007 and 2010 were identified(More)
INTRODUCTION In New Zealand, prostate-specific antigen (PSA) testing has increased significantly (275 000 tests/year). Controversy exists around PSA testing as part of an unorganised screening programme. AIM To look at the use of PSA testing in a sample of general practices and investigate the reasons GPs undertake PSA testing. METHODS Five Waikato(More)
OBJECTIVES Antipsychotics are the cornerstone of schizophrenia management. There is substantial literature on their efficacy and optimal use. Doubts remain, however, regarding the translation of this knowledge into day-to-day practice. This study aimed to investigate antipsychotic prescribing in three New Zealand regions and its relationship to clinical(More)
BACKGROUND Screening for prostate cancer (PCa) using the prostate-specific antigen (PSA) test is widespread in New Zealand. Aim. This study estimates the costs of identifying a new case of PCa by screening asymptomatic men. METHODS Men aged 40+, who had PSA tests in 31 general practices in the Midland Cancer Network region during 2010, were identified.(More)
PURPOSE To examine prostate-specific antigen (PSA) screening patterns and outcomes in rural and urban men in New Zealand. METHODS Men aged 40+ years were identified from 18 rural and 13 urban general practices across the Midland Cancer Network region. Computerized practice records were cross-referenced with community laboratory data to ascertain the(More)